CS
REGN icon

Crescent Sterling’s Regeneron Pharmaceuticals REGN Stock Holding History

Crescent Sterling’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-279
Closed -$215K – 83
2025
Q4 		$215K Buy
+279
New +$189K 0.22% 75
2025
Q2 		– Sell
-411
Closed -$261K – 78
2025
Q1 		$261K Buy
411
+9
+2% +$6.19K 0.27% 69
2024
Q4 		$286K Sell
402
-15
-4% -$12.6K 0.29% 67
2024
Q3 		$438K Sell
417
-16
-4% -$17.8K 0.42% 56
2024
Q2 		$455K Hold
433
– – 0.44% 57
2024
Q1 		$417K Sell
433
-7
-2% -$6.66K 0.38% 58
2023
Q4 		$386K Hold
440
– – 0.39% 57
2023
Q3 		$362K Sell
440
-19
-4% -$14.9K 0.38% 56
2023
Q2 		$330K Hold
459
– – 0.31% 60
2023
Q1 		$377K Buy
459
+16
+4% +$12.1K 0.37% 56
2022
Q4 		$320K Buy
+443
New +$327K 0.34% 55

Other funds holding REGN

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return